No Data
No Data
BTIG Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $6
Ginkgo Bioworks Holdings Full Year 2024 Earnings: EPS Misses Expectations
Ginkgo Bioworks Falls -12.5%
Express News | Ginkgo Bioworks Holdings Shares Are Trading Lower After the Company Reported Worse-than-expected Q4 Financial Results and Issued FY25 Revenue Guidance Below Estimates
Goldman Sachs Maintains Ginkgo Bioworks(DNA.US) With Sell Rating, Maintains Target Price $7
Cautious Outlook on Ginkgo Bioworks: Sell Rating Amid Financial and Strategic Concerns